U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07145411) titled 'HPC Offered for PRESERVE Expansion' on July 10.

Brief Summary: Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Study Start Date: June 27, 2024

Study Type: OBSERVATIONAL

Condition: Bone Marrow Transplant (BMT)

Intervention: OTHER: Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)

The HOPE Program does not include any investigational drugs. The medicines and pro...